Marielle Cohard-Radice

Marielle Cohard-Radice serves as an Independent Director and Board Member at Neurenati Therapeutics since May 2024. Prior to this role, extensive experience includes positions at Daiichi Sankyo, Inc. from January 2012 to July 2025, where responsibilities included EVP, Global Head of Development Operations, and EVP Global Head of Development, overseeing Clinical Operations, TMF Operations, Medical Writing, and Quality Management. Additionally, Marielle was the president of Daiichi Sankyo Oncology France from May 2021 to May 2024. Earlier career highlights include leadership roles at Aptalis Pharmaceutical Technologies, Axcan Pharma, Novartis, and Schering-Plough Research Institute, spanning areas such as clinical development, medical safety, and scientific direction. Marielle holds an MD from Université Joseph Fourier (Grenoble I) and a diploma in Medical Applications of Statistics from Pierre and Marie Curie University.